Lv0
0 积分 2024-05-18 加入
Visible-Light-Induced Iron Group Metal Catalysis: Recent Developments in Organic Synthesis
2天前
已完结
Abstract 1209: Comprehensive in vitro characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor
2个月前
已关闭
Preclinical and clinical pharmacology of EPI-7386, an androgen receptor N-terminal domain inhibitor for castration-resistant prostate cancer
2个月前
已完结
SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain
3个月前
已完结
EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy
3个月前
已完结
N-terminal domain of androgen receptor is a major therapeutic barrier and potential pharmacological target for treating castration resistant prostate cancer: a comprehensive review
3个月前
已完结
Amidoselenation of Alkenes Yielding the β-Amido-selenides through a Radical Pathway
4个月前
已完结
794P - EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 update on safety, tolerability, pharmacokinetics and efficacy
6个月前
已完结
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
6个月前
已完结
503P - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
6个月前
已完结
皖公网安备34019202002308
